David J Rawlings MD
Professor, Pediatrics, University of Washington School of Medicine
Join to View Full Profile
4800 Sand Point Way NeSeattle, WA 98105
Phone+1 206-987-2000
Dr. Rawlings is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of North Carolina at Chapel Hill School of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1986 - Present
WA State Medical License 2001 - 2026
MD State Medical License 1988 - 1991
American Board of Pediatrics Pediatric Rheumatology
Clinical Trials
- Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Start of enrollment: 2016 Aug 17
Publications & Presentations
PubMed
- Reduced function of the adaptor SH2B3 promotes T1D via altered cytokine-regulated, T cell intrinsic immune tolerance.Taylor K Watson, Aaron B I Rosen, Travis Drow, Jacob A Medjo, Matthew A MacQuivey
Diabetes. 2025-03-06 - Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells.Christopher D Thouvenel, Christopher M Tipton, Yasuhiro Yamazaki, Ting-Ting Zhang, Stacey Rylaarsdam
Journal of Clinical Immunology. 2025-01-15 - Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice.Yuchi Honaker, David Gruber, Chester Jacobs, Rene Yu-Hong Cheng, Shivani Patel
Molecular Therapy. 2024-12-12
Journal Articles
- Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B CellsDavid J Rawlings, Shaun W Jackson, The Journal of Immunology
Abstracts/Posters
- Enabling Gene-Edited, Regulatory-like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune DisordersDavid J. Rawlings, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Manufacture and In Vivo Support of Gene-Edited, Regulatory-like, T-Cells (edTreg) Using a Synthetic IL2 ReceptorDavid J. Rawlings, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Emendo Biotherapeutics and Seattle Children’s Research Institute Announce Collaboration to Develop CRISPR-Based Therapeutic Strategy for Severe Congenital NeutropeniaDecember 22nd, 2021
- Seattle Children’s Research Division: Celebrating 15 Years of InnovationNovember 12th, 2021
Seattle Children’s Licenses Gene-Editing Therapy to Casebia Therapeutics and Will Partner on Further ResearchSeptember 27th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
